靶向治疗与一种增强癌细胞终末分化的药物联合使用。

Targeted Therapy in Combination with an Agent That Enhances Terminal Differentiation of Cancer Cells.

作者信息

Shramova E I, Proshkina G M, Zavestovskaya I N, Deyev S M

机构信息

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Lebedev Physical Institute, Russian Academy of Sciences, Moscow, Russia.

出版信息

Dokl Biol Sci. 2025 Apr;521(1):152-155. doi: 10.1134/S0012496624600702. Epub 2025 Apr 11.

DOI:10.1134/S0012496624600702

PMID:40216677

Abstract

Currently, in addition to standard methods, an approach is being developed for the treatment of oncological diseases in which terminal differentiation of cancer cells is induced by pharmacological drugs, which increases the response to traditional treatment methods. According to literature data, dimethyl sulfoxide (DMSO) is a safe adjuvant that stimulates the differentiation of various types of the cancer cells. A method proposed in the article was designed to eliminate SKOV3.ip1 human ovarian cancer cell adenocarcinomas by combining targeted therapy based on the HER2-specific toxin DARPin-LoPE and treatment with DMSO as an enhancing agent for terminal differentiation of cancer cells.

摘要

目前，除了标准方法外，一种治疗肿瘤疾病的方法正在研发中，即通过药物诱导癌细胞终末分化，这提高了对传统治疗方法的反应。根据文献数据，二甲基亚砜（DMSO）是一种安全的佐剂，可刺激各类癌细胞的分化。本文提出的一种方法旨在通过结合基于HER2特异性毒素DARPin-LoPE的靶向治疗以及使用DMSO作为癌细胞终末分化增强剂的治疗，来消除SKOV3.ip1人卵巢癌细胞腺癌。